DTIL

Precision Biosciences Inc.

A clinical-stage gene editing company whose ARCUS platform, built on a naturally occurring enzyme first found in green algae, develops therapies for chronic hepatitis B and Duchenne muscular dystrophy. Three Duke University postdocs founded the company in 2006 after their lab discovery placed second in a university start-up challenge, and the earliest ARCUS work actually edited crops like corn and soybean before turning to human medicines.